Cargando…

Substrate-specific binding and conformational changes involving Ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking

RFC (reduced folate carrier) is the major transporter for reduced folates and antifolates [e.g. MTX (methotrexate)]. RFC is characterized by two halves, each with six TMD (transmembrane domain) α helices connected by a hydrophilic loop, and cytoplasmic N- and C-termini. We previously identified TMDs...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Zhanjun, Wu, Jianmei, Ye, Jun, Cherian, Christina, Matherly, Larry H.
Formato: Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947195/
https://www.ncbi.nlm.nih.gov/pubmed/20557288
http://dx.doi.org/10.1042/BJ20100181
_version_ 1782187367312916480
author Hou, Zhanjun
Wu, Jianmei
Ye, Jun
Cherian, Christina
Matherly, Larry H.
author_facet Hou, Zhanjun
Wu, Jianmei
Ye, Jun
Cherian, Christina
Matherly, Larry H.
author_sort Hou, Zhanjun
collection PubMed
description RFC (reduced folate carrier) is the major transporter for reduced folates and antifolates [e.g. MTX (methotrexate)]. RFC is characterized by two halves, each with six TMD (transmembrane domain) α helices connected by a hydrophilic loop, and cytoplasmic N- and C-termini. We previously identified TMDs 4, 5, 7, 8, 10 and 11 as forming the hydrophilic cavity for translocation of (anti)folates. The proximal end of TMD8 (positions 311–314) was implicated in substrate binding from scanning-cysteine accessibility methods; cysteine replacement of Ser(313) resulted in loss of transport. In the present study, Ser(313) was mutated to alanine, cysteine, phenylalanine and threonine. Mutant RFCs were expressed in RFC-null R5 HeLa cells. Replacement of Ser(313) with cysteine or phenylalanine abolished MTX transport, whereas residual activity was preserved for the alanine and threonine mutants. In stable K562 transfectants, S313A and S313T RFCs showed substantially decreased V(max) values without changes in K(t) values for MTX compared with wild-type RFC. S313A and S313T RFCs differentially impacted binding of ten diverse (anti)folate substrates. Cross-linking between TMD8 and TMD5 was studied by expressing cysteine-less TMD1–6 (N(6)) and TMD7–12 (C(6)) half-molecules with cysteine insertions spanning these helices in R5 cells, followed by treatment with thiol-reactive homobifunctional cross-linkers. C(6)–C(6) and N(6)–N(6) cross-links were seen for all cysteine pairs. From the N(6) and C(6) cysteine pairs, Cys(175)/Cys(311) was cross-linked; cross-linking increased in the presence of transport substrates. The results of the present study indicate that the proximal end of TMD8 is juxtaposed to TMD5 and is conformationally active in the presence of transport substrates, and TMD8, including Ser(313), probably contributes to the RFC substrate-binding domain.
format Text
id pubmed-2947195
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-29471952010-10-04 Substrate-specific binding and conformational changes involving Ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking Hou, Zhanjun Wu, Jianmei Ye, Jun Cherian, Christina Matherly, Larry H. Biochem J Research Article RFC (reduced folate carrier) is the major transporter for reduced folates and antifolates [e.g. MTX (methotrexate)]. RFC is characterized by two halves, each with six TMD (transmembrane domain) α helices connected by a hydrophilic loop, and cytoplasmic N- and C-termini. We previously identified TMDs 4, 5, 7, 8, 10 and 11 as forming the hydrophilic cavity for translocation of (anti)folates. The proximal end of TMD8 (positions 311–314) was implicated in substrate binding from scanning-cysteine accessibility methods; cysteine replacement of Ser(313) resulted in loss of transport. In the present study, Ser(313) was mutated to alanine, cysteine, phenylalanine and threonine. Mutant RFCs were expressed in RFC-null R5 HeLa cells. Replacement of Ser(313) with cysteine or phenylalanine abolished MTX transport, whereas residual activity was preserved for the alanine and threonine mutants. In stable K562 transfectants, S313A and S313T RFCs showed substantially decreased V(max) values without changes in K(t) values for MTX compared with wild-type RFC. S313A and S313T RFCs differentially impacted binding of ten diverse (anti)folate substrates. Cross-linking between TMD8 and TMD5 was studied by expressing cysteine-less TMD1–6 (N(6)) and TMD7–12 (C(6)) half-molecules with cysteine insertions spanning these helices in R5 cells, followed by treatment with thiol-reactive homobifunctional cross-linkers. C(6)–C(6) and N(6)–N(6) cross-links were seen for all cysteine pairs. From the N(6) and C(6) cysteine pairs, Cys(175)/Cys(311) was cross-linked; cross-linking increased in the presence of transport substrates. The results of the present study indicate that the proximal end of TMD8 is juxtaposed to TMD5 and is conformationally active in the presence of transport substrates, and TMD8, including Ser(313), probably contributes to the RFC substrate-binding domain. Portland Press Ltd. 2010-08-13 2010-09-01 /pmc/articles/PMC2947195/ /pubmed/20557288 http://dx.doi.org/10.1042/BJ20100181 Text en © 2010 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by-nc/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hou, Zhanjun
Wu, Jianmei
Ye, Jun
Cherian, Christina
Matherly, Larry H.
Substrate-specific binding and conformational changes involving Ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking
title Substrate-specific binding and conformational changes involving Ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking
title_full Substrate-specific binding and conformational changes involving Ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking
title_fullStr Substrate-specific binding and conformational changes involving Ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking
title_full_unstemmed Substrate-specific binding and conformational changes involving Ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking
title_short Substrate-specific binding and conformational changes involving Ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking
title_sort substrate-specific binding and conformational changes involving ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947195/
https://www.ncbi.nlm.nih.gov/pubmed/20557288
http://dx.doi.org/10.1042/BJ20100181
work_keys_str_mv AT houzhanjun substratespecificbindingandconformationalchangesinvolvingser313andtransmembranedomain8ofthehumanreducedfolatecarrierasdeterminedbysitedirectedmutagenesisandproteincrosslinking
AT wujianmei substratespecificbindingandconformationalchangesinvolvingser313andtransmembranedomain8ofthehumanreducedfolatecarrierasdeterminedbysitedirectedmutagenesisandproteincrosslinking
AT yejun substratespecificbindingandconformationalchangesinvolvingser313andtransmembranedomain8ofthehumanreducedfolatecarrierasdeterminedbysitedirectedmutagenesisandproteincrosslinking
AT cherianchristina substratespecificbindingandconformationalchangesinvolvingser313andtransmembranedomain8ofthehumanreducedfolatecarrierasdeterminedbysitedirectedmutagenesisandproteincrosslinking
AT matherlylarryh substratespecificbindingandconformationalchangesinvolvingser313andtransmembranedomain8ofthehumanreducedfolatecarrierasdeterminedbysitedirectedmutagenesisandproteincrosslinking